EHA: Vertex, CRISPR build case for gene-editing drug
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, EHA 2022, gene editing, sickle cell disease, Vertex Pharma
0 Comment
Vertex Pharma
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma
0 Comment
Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance
CRISPR Therapeutics, CRISPR/Cas9, gene editing, Obsidian Therapeutics, partnering, Vertex Pharma
0 Comment
FDA fast tracks type 1 diabetes cell therapy from Vertex
cell therapy, fda, FDA fast track, Regenerative medicine, type 1 diabetes, Vertex Pharma
0 Comment
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex Pharma
0 Comment
Vertex gets EU okay to treat younger cystic fibrosis patients
cystic fibrosis, ema, Kalydeco, regulatory approval, Symkevi, Vertex Pharma
0 Comment
Vertex Pharma’s vision for reimbursement innovation
COVID-19, cystic fibrosis, EU Leaders, NICE, reimbursement, UK Leaders, Vertex Pharma
0 Comment
1 2